Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

CD123 may be a marker for residual disease and response evaluation in AML and B-ALL

Key clinical point: CD123 may be considered as a cardinal marker for residual disease assessment and response evaluation in AML and B-ALL.

Major finding: CD123 expression was associated with MRD positive status in both B-ALL (P < .001) and AML (P = .001).

Study details: A total of 757 samples of acute leukemia including 479 treatment naive and 278 follow-up samples were compared.

Disclosures: The authors reported that they had no conflicts of interest.

Citation:

Das N et al. Clin Lymphoma Myeloma Leuk. 2020 May 10; doi.org/10.1016/j.clml.2020.05.004.